APPLICATION
ANDA213244
TYPE
ANDA
ORIGINAL APPROVAL
2023-11-02
LATEST ACTION
2024-10-25
ROUTE
INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE, SOLUTION
MARKETING STATUS
Prescription, Discontinued
Products
NEOSTIGMINE METHYLSULFATEPrescription
NEOSTIGMINE METHYLSULFATE 10MG/10ML(1MG/ML) · INJECTABLE · INJECTION
NEOSTIGMINE METHYLSULFATEDiscontinued
NEOSTIGMINE METHYLSULFATE 10MG/10ML (1MG/ML) · SOLUTION · INTRAVENOUS
NEOSTIGMINE METHYLSULFATEPrescription
NEOSTIGMINE METHYLSULFATE 5MG/10ML(0.5MG/ML) · INJECTABLE · INJECTION
NEOSTIGMINE METHYLSULFATEDiscontinued
NEOSTIGMINE METHYLSULFATE 5MG/10ML (0.5MG/ML) · SOLUTION · INTRAVENOUS
Approval history
2024-10-25Labeling · Supplement 2 · standardAP
2023-11-02UNKNOWN · Original · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.